Literature DB >> 33567541

Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma.

Rosario Aschero1,2, Jasmine H Francis3, Daiana Ganiewich4, Soledad Gomez-Gonzalez5, Claudia Sampor6, Santiago Zugbi2,7, Daniela Ottaviani8, Lauriane Lemelle8, Marcela Mena7, Ursula Winter1, Genoveva Correa Llano9, Gabriela Lamas1, Fabiana Lubieniecki1, Irene Szijan10, Jaume Mora5,9, Osvaldo Podhajcer2,4, François Doz8, François Radvanyi8, David H Abramson3, Andrea S Llera2,4, Paula S Schaiquevich2,7, Cinzia Lavarino5,9, Guillermo L Chantada2,9.   

Abstract

Most reports about copy number alterations (CNA) in retinoblastoma relate to patients with intraocular disease and features of children with extraocular relapse remain unknown, so we aimed to describe the CNA in this population. We evaluated 23 patients and 27 specimens from 4 centers. Seventeen cases had extraocular relapse after initial enucleation and six cases after an initial preservation attempt. We performed an analysis of CNA and BCOR gene alteration by SNP array (Single Nucleotide Polymorfism array), whole-exome sequencing, IMPACT panel and CGH array (Array-based comparative genomic hybridization). All cases presented CNA at a higher prevalence than those reported in previously published studies for intraocular cases. CNA previously reported for intraocular retinoblastoma were found at a high frequency in our cohort: gains in 1q (69.5%), 2p (60.9%) and 6p (86.9%), and 16q loss (78.2%). Other, previously less-recognized, CNA were found including loss of 11q (34.8%), gain of 17q (56.5%), loss of 19q (30.4%) and BCOR alterations were present in 72.7% of our cases. A high number of CNA including 11q deletions, 17q gains, 19q loss, and BCOR alterations, are more common in extraocular retinoblastoma. Identification of these features may be correlated with a more aggressive tumor warranting consideration for patient management.

Entities:  

Keywords:  BCOR mutations; copy number alteration; extraocular retinoblastoma; genomic; metastasis

Year:  2021        PMID: 33567541      PMCID: PMC7915502          DOI: 10.3390/cancers13040673

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  40 in total

1.  Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Authors:  Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.

Authors:  Corinna Grasemann; Sandrine Gratias; Harald Stephan; Andreas Schüler; Alexander Schramm; Ludger Klein-Hitpass; Harald Rieder; Stephanie Schneider; Ferdinand Kappes; Angelika Eggert; Dietmar R Lohmann
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

3.  Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization.

Authors:  Boris Zielinski; Sandrine Gratias; Grischa Toedt; Frank Mendrzyk; Daniel E Stange; Bernhard Radlwimmer; Dietmar R Lohmann; Peter Lichter
Journal:  Genes Chromosomes Cancer       Date:  2005-07       Impact factor: 5.006

4.  Chromosome 6p Amplification in Aqueous Humor Cell-Free DNA Is a Prognostic Biomarker for Retinoblastoma Ocular Survival.

Authors:  Liya Xu; Ashley Polski; Rishvanth K Prabakar; Mark W Reid; Patricia Chevez-Barrios; Rima Jubran; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Mol Cancer Res       Date:  2020-05-20       Impact factor: 5.852

5.  Accumulation of segmental alterations determines progression in neuroblastoma.

Authors:  Gudrun Schleiermacher; Isabelle Janoueix-Lerosey; Agnès Ribeiro; Jerzy Klijanienko; Jérôme Couturier; Gaëlle Pierron; Véronique Mosseri; Alexander Valent; Nathalie Auger; Dominique Plantaz; Hervé Rubie; Dominique Valteau-Couanet; Franck Bourdeaut; Valérie Combaret; Christophe Bergeron; Jean Michon; Olivier Delattre
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Minimal 16q genomic loss implicates cadherin-11 in retinoblastoma.

Authors:  Mellone N Marchong; Danian Chen; Timothy W Corson; Cheong Lee; Maria Harmandayan; Ella Bowles; Ning Chen; Brenda L Gallie
Journal:  Mol Cancer Res       Date:  2004-09       Impact factor: 5.852

7.  Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.

Authors:  H Caron; P van Sluis; J de Kraker; J Bökkerink; M Egeler; G Laureys; R Slater; A Westerveld; P A Voûte; R Versteeg
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

8.  Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation.

Authors:  Isabelle Aerts; Xavier Sastre-Garau; Alexia Savignoni; Livia Lumbroso-Le Rouic; Estelle Thebaud-Leculée; Didier Frappaz; Carole Coze; Caroline Thomas; Marion Gauthier-Villars; Christine Lévy-Gabriel; Hervé J Brisse; Laurence Desjardins; François Doz
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

9.  Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome.

Authors:  Debra M Lillington; Judith E Kingston; Pietro G Coen; Elizabeth Price; John Hungerford; Paola Domizio; Bryan D Young; Zerrin Onadim
Journal:  Genes Chromosomes Cancer       Date:  2003-02       Impact factor: 5.006

10.  Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.

Authors:  Tasnim Chagtai; Christina Zill; Linda Dainese; Jenny Wegert; Suvi Savola; Sergey Popov; William Mifsud; Gordan Vujanić; Neil Sebire; Yves Le Bouc; Peter F Ambros; Leo Kager; Maureen J O'Sullivan; Annick Blaise; Christophe Bergeron; Linda Holmquist Mengelbier; David Gisselsson; Marcel Kool; Godelieve A M Tytgat; Marry M van den Heuvel-Eibrink; Norbert Graf; Harm van Tinteren; Aurore Coulomb; Manfred Gessler; Richard Dafydd Williams; Kathy Pritchard-Jones
Journal:  J Clin Oncol       Date:  2016-07-18       Impact factor: 44.544

View more
  2 in total

1.  Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma: A Multicenter Registry-Based Study.

Authors:  Ankit Singh Tomar; Paul T Finger; Brenda Gallie; Tero T Kivelä; Ashwin Mallipatna; Chengyue Zhang; Junyang Zhao; Matthew W Wilson; Rachel C Brennan; Michala Burges; Jonathan Kim; Jesse L Berry; Rima Jubran; Vikas Khetan; Suganeswari Ganesan; Andrey Yarovoy; Vera Yarovaya; Elena Kotova; Denis Volodin; Yacoub A Yousef; Kalle Nummi; Tatiana L Ushakova; Olga V Yugay; Vladimir G Polyakov; Marco A Ramirez-Ortiz; Elizabeth Esparza-Aguiar; Guillermo Chantada; Paula Schaiquevich; Adriana Fandino; Jason C Yam; Winnie W Lau; Carol P Lam; Phillipa Sharwood; Sonia Moorthy; Quah Boon Long; Vera Adobea Essuman; Lorna A Renner; Ekaterina Semenova; Jaume Català-Mora; Genoveva Correa-Llano; Elisa Carreras
Journal:  Ophthalmology       Date:  2022-04-30       Impact factor: 14.277

Review 2.  The Impact of Cell-Free DNA Analysis on the Management of Retinoblastoma.

Authors:  Amy Gerrish; Helen Jenkinson; Trevor Cole
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.